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OBJECTIVE — Weassessedtheeffectsofa2-dayin-hospitaldiabeteseducationalprogramin
preventing or delaying progression of impaired glucose tolerance (IGT) to type 2 diabetes,
including analysis of changes in serum lipids, body weight, and blood pressure after the program.
RESEARCH DESIGN AND METHODS — A total of 426 subjects (51  9 years, BMI
24.6  3.9 kg/m
2) with newly diagnosed IGT were randomly assigned to three groups, 143 as
the short-term hospitalization with diabetes education and support (STH) group, 141 as the
nonhospitalization but diabetes education and support (DES) group, and 142 as the neither
hospitalization nor education (control) group.
RESULTS — The average follow-up was 3.1 years. The incidence of diabetes was 8.0, 10.7,
and 13.2 cases per 100 person-years for STH, DES, and control groups, respectively. The
incidence of diabetes was 42% lower (95% CI 33–51%) in the STH group and 27% lower
(15–37%) in the DES group than in the control group. The incidence of diabetes was 21% lower
(10–31%) in the STH group than in the DES group.
CONCLUSIONS — The 2-day in-hospital program with diabetes education and support
every3monthswasmoreeffectiveinpreventingordelayingtheprogressionfromIGTtodiabetes
than only diabetes education and support every 3 months.
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I
n recent years, the number of new pa-
tients with type 2 diabetes and im-
paired glucose tolerance (IGT) has
increased steadily around the world, and
it is estimated that 300 million people
worldwide will have type 2 diabetes by
the year 2025 (1). Based on many large-
scale clinical studies, it is clear that IGT is
a major risk factor for cardiovascular dis-
ease (2–4). It is also clear that the preven-
tion of diabetes before its onset and
treatment of this disease in its early stages
are important from the perspective of
public health, medical treatment, and
economic management (5). Thus, there
have been several intervention studies
with lifestyle modiﬁcation that have
demonstrated positive effects (5–8).
However, in these studies, intensive
monitoring was required, and there are
many difﬁculties in carrying out similar
interventions in general clinics. For ex-
ample, in the Diabetes Prevention Pro-
gram (DPP), only 38% of the
participants in the intensive lifestyle in-
tervention group had achieved the goal
weight loss of 7% after 3 years. Fur-
thermore, the program required the co-
operation of many staff and substantial
costs (6,7). Based on this background,
we designed a 2-day in-hospital, simple
andeasy-to-applyeducationalprogram.
The aim of this study was to assess the
efﬁcacy of such a program with diabetes
education and support every 3 months
inpreventingordelayingprogressionto
type 2 diabetes in patients with IGT.
RESEARCH DESIGN AND
METHODS— We recruited the par-
ticipantsfrom11outpatientpracticesand
a health evaluation and promotion center
in the Joetsu area. The study was a com-
munity-based clinical trial. All partici-
pants were followed up at Niigata-Rousai
Hospital using the prospective random-
izedopenblindedendpoint(PROBE)de-
sign, which aims to create conditions
similartoroutineclinicalpractice(9).We
screened for patients aged 20–70 years,
with BMI 20–34 kg/m
2, fasting plasma
glucose concentration 100 mg/dl, or
A1C level between 5.2 and 6.4%. The pa-
tients were eligible for our study if they
hadIGT,deﬁnedasaplasmaglucosecon-
centration125mg/dlinthefastingstate
and 140–199 mg/dl 2 h after a 75-g oral
glucose load, according to the 2003
American Diabetes Association criteria
(8).Inaddition,allparticipantswerecon-
ﬁrmed to have systolic blood pressure
150 mmHg, diastolic blood pressure
100 mmHg, total cholesterol 300
mg/dl, triglycerides 220 mg/dl, and
LDL cholesterol 180 mg/dl and were not
takinganymedicationthatmightaffectgly-
cemic control. All end points were assessed
by an independent end point committee,
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ment status of the participants.
Written informed consent was ob-
tained from all participants. The medical
ethical committees of our hospital ap-
proved the trial protocol.
Interventions
Eligible participants were randomly as-
signed to one of three groups: the short-
term hospitalization with diabetes
supportandeducation(STH)group,non-
hospitalization but diabetes education
and support (DES) group, or neither hos-
pitalization nor education (control)
group.Randomizationwasdonecentrally
with a block design procedure and strati-
ﬁed according to age (three groups: 20–
44, 45–59, and 60–70 years) and sex
(two groups: male and female). The par-
ticipant randomization list was kept in a
securelocationatacentralcoordination
center and was not available to any
individual.
In the control group, participants
were given general information about di-
abetesandIGT.Theirphysiciansalsopro-
vided diabetes information brochures
with general instructions for diet and im-
provement of lifestyle; however, no indi-
vidual instruction or formal group
counseling sessions were conducted.
In the STH group, participants re-
ceived a nine-lesson curriculum, de-
signed as a clinical course, covering
special diet, exercise, and behavior mod-
iﬁcationtohelpthemchangetheirbehav-
ior (supplemental Fig. 2 available in an
online appendix at http://dx.doi.org/10.
2337/dc07-2272). In a preliminary trial
(T.K., K.T., T.A., T.T., Y.O., E.M., Y.T.,
unpublishedobservations),wefoundthat
a2-dayhospitalstayandninelessonshad
a maximal effect in maintaining motiva-
tion and in understanding diabetes and
IGT. This was less costly than a 3-day or
longer hospital stay and was also more
effective than a 1-day hospital stay; there-
fore, we selected these parameters. Les-
sons were taught by nutritionists,
pharmacists, physical therapists, nurses,
medical technologists, and physicians on
a one-to-one or group basis, and each
lesson, which lasted 20–40 min, was
ﬂexible, culturally sensitive, and individ-
ualized. We set the diet at 25–30 kcal/kg
of ideal body weight for each participant,
and the goal of dietary intervention was a
total daily intake of fat that was 20–
25% of daily energy intake. In addition,
participants received exercise therapy in
the form of participation in a traditional
Japanesephysicalexerciseradioprogram.
We instructed the participants to con-
tinue walking or doing the radio exercise
routine for at least 30 min/day, a mini-
mum of 5 times a week after discharge
from hospital. Subsequent individual ses-
sions every 3 months with nurses or
nutritionists,designedtoreinforcethebe-
havioral changes, were similar to the pro-
gram received by participants in the DES
group.
In the DES group, participants were
provided with written information and
periodic 20- to 30-min individual ses-
sionsthatemphasizedtheimportanceofa
healthy lifestyle. Participants were en-
couraged to follow the diabetes guide-
book (10) issued by the Japan Diabetes
Society. They were also instructed to fol-
low the equivalent of the food guidebook
(11) to reduce their weight and to in-
crease their physical activity.
Our study steering committee pro-
vided the guidelines, in which informa-
tion about various teaching methods was
described, to all staff involved in the
study. All of the staff attended a 2-day
training session each year in which they
received standardized instructions on the
diet and exercise interventions.
Follow-up procedures
All participants were given a reminder in
which outpatient guidance was noted ev-
ery 3 months. They were also seen at
3-month intervals by their physicians.
Body weight, waist circumference, and
bloodpressureweremeasured,andblood
and urine samples were taken for exami-
nation. The general health of each partic-
ipant was assessed, and the results of
blood and urine examinations were ex-
plained by the physician. Physicians gave
advice about diabetes or IGT for 5–10
minineveryinterview.Thereafter,partic-
ipants in the STH and DES groups re-
ceived 20- to 30-min individual sessions
as described above. All participants were
surveyed at baseline and every 6 months
about their adherence to recommenda-
tions. Self-assessment reports that re-
ferred to the DPS method were used for
the survey (12).
The primary end point was the devel-
opment of diabetes, diagnosed on the ba-
sis of an annual 75-g oral glucose
tolerance test (OGTT) or a fasting plasma
glucose check at every 3-month visit, ac-
cording to the 2003 criteria of the Amer-
ican Diabetes Association (8): a plasma
glucose value of 126 mg/dl in the fast-
ing state or 200 mg/dl 2 h after taking a
75-g oral glucose load (Trelan-G75). All
participants underwent the OGTT annu-
ally,butifthefastingplasmaglucosecon-
centration was 126 mg/dl at any
3-month visit, the participant was auto-
matically scheduled to undergo an OGTT
within 4 weeks. Participants who reached
the primary end point discontinued this
study. In addition, if total cholesterol in-
creasedto300mg/dlortriglyceridesin-
creasedto220mg/dlorLDLcholesterol
increasedto180mg/dl,theparticipants
discontinued this study and treatment
with hypolipidemic agents was initiated
by their physicians.
Laboratory investigations
All blood samples were transferred to the
central laboratory at Niigata-Rousai Hos-
pital, and aliquots were stored at 70°C
until use. Plasma glucose levels were de-
termined by the glucose oxidation
method (chemical reagent and Glucose
AUTO and STAT GA-1160 analyzer;
ARKRAY). A1C (normal value 4.0–5.8%)
was measured by high-performance liq-
uid chromatography (ADAMS A1c HA-
8160; ARKRAY). Total cholesterol and
triglycerides were measured by choles-
terol oxidation enzyme and enzymatic
colorimetry methods (Daiichi-kayaku,
H-7700; Hitachi). LDL cholesterol was
measured by the direct method without
deposition (Daiichi-kayaku H-7700).
Costs estimate
In our analyses, we followed the recom-
mendations of the Panel on Cost-
EffectivenessinHealthandMedicine(13)
and the method of estimating the costs in
the Diabetes Prevention Program (14). In
all analyses from a health system perspec-
tive, we included only direct medical
costs. In analyses from a societal perspec-
tive, we included direct medical costs, di-
rect nonmedical costs, and indirect costs
to estimate the cost per case of diabetes
prevented during the trial. We used the
exchange rates in 2000 (1 U.S. dollar
equal to 120 Japanese yen).
Statistical analysis
Ontheassumptionofaconversionrateof
13% per year and a 40% risk reduction,
we estimated that 138 patients were re-
quired in each of the three groups to
achieve 80% power to detect a signiﬁcant
difference with a two-sided  error of
0.05. An intention-to-treat analysis that
includedallpatientsintheirassignedtrial
groups, regardless of whether they actu-
ally underwent intervention, was per-
formed. Cox proportional hazards
Diabetes educational program and diabetes
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tiosand95%CIfortheprimaryendpoint
and to perform an analysis of the primary
end point adjusted for age and sex. We
used non–repeated-measures ANOVA
and the 
2 test to compare the baseline
variables between the three groups. We
used person-years: total number of the
participants who developed diabetes/
summation of follow-up years of each
participant, to show the incidence rate.
We assessed changes in variables from
baseline to the end point with repeated-
measures ANOVA and the Bonferroni
correction. All tests were two-tailed, and
P values 0.05 were considered to indi-
cate statistical signiﬁcance. Statistical
analysis was performed using Sigma Stat
software (SPSS, Chicago, IL). All data are
represented as means  SD.
RESULTS— From June 2003 to July
2007, we randomly assigned 426 partici-
pants to one of the three groups (143 to
STH, 141 to DES, and 142 to control)
(supplemental Fig. 1). No signiﬁcant dif-
ferences were found in the baseline char-
acteristics, including all measured risk
factors for diabetes, among the three
study groups (Table 1). The participants
were followed for a mean period of 3.1
years (range 1.8–4.2).
Attendance at follow-up visits was al-
most the same in each group (STH 97%,
DES 96%, and control 94%). There were
no signiﬁcant differences in the adher-
ence to recommendations (measure of
physical activity and diet composition)
amongthethreegroups(datanotshown).
Incidence of diabetes and change in
glucose parameters
The incidence of diabetes was 8.0, 10.7,
and 13.2 cases per 100 person-years in
the STH, DES, and control groups, re-
spectively (Fig. 1). The incidence of dia-
beteswas42%lower(95%CI33–51%)in
the STH group and 27% lower (95% CI
15–37%) in the DES group than in the
control group. The incidence of diabetes
was 21% lower (95% CI 10–31%) in the
STH group than in the DES group. The
results of all three pairwise group com-
parisonswerestatisticallysigniﬁcant(P
0.01). The estimated cumulative inci-
dence of diabetes at 3 years was 23.9,
29.6, and 38.8% in the STH, DES, and
control groups, respectively. On the basis
of these rates, the number needed to treat
to prevent one case of diabetes was seven
(95% CI 5–11) in the STH group and 11
(95% CI 8–16) in the DES group over 3
years.
Fasting plasma glucose, 2-h OGTT
plasma glucose, and A1C increased gradu-
ally in all three groups over the 3-year fol-
low-up in comparison with baseline values
(P0.01).Changesinthethreeparameters
over the 3-year period were signiﬁcantly
differentamongthethreegroups(P0.01)
(Fig. 2A–C).
Changes in body weight, waist
circumference, and systolic blood
pressure
Participants in the STH group showed a
greater weight loss than those in the DES
and control groups (Fig. 2D). The mean
changes in weight at the 3-year follow-up
were 2.1, 1.2, and 0.4 kg in the
STH, DES, and control groups, respec-
tively (P  0.01). When we analyzed the
incidence of diabetes adjusted by the
change in body weight, there were no sig-
niﬁcant differences among three groups
(STH vs. control P  0.054; STH vs. DES
P  0.067; and DES vs. control P 
0.059).
Waist circumference increased in all
groups over 3 years in comparison with the
baselinevalues(P0.01).Changesinwaist
circumference over the 3-year period
among the three groups were signiﬁcantly
different(P0.01)(supplementalFig.3A).
Therewasnosigniﬁcantdifferencebetween
the STH and DES groups in systolic blood
pressure, but the values of the two groups
were signiﬁcantly lower than that in the
control group (P  0.01) (supplemental
Fig. 3B).
Changes in serum lipids
(triglycerides and total, LDL, and
HDL cholesterol)
Serum triglycerides increased gradually
in all three groups over the 3-year fol-
low-up in comparison with baseline val-
ues (P  0.01). Changes in serum
triglycerides over the 3-year period were
signiﬁcantly different among the three
groups (P  0.01).
Total cholesterol of the control group
increased signiﬁcantly in comparison
with baseline values (P  0.01). On the
other hand, that of the STH and DES
groups decreased over the 3-year period.
Changes in total cholesterol over the
Table 1—Baseline characteristics of participants in the STH, DES, and control groups
All subjects STH DES Control
n 426 143 141 142
Age (years) 51.4  9.1 52.6  8.9 51.1  9.3 51.8  9.2
Sex (male/female) 199/227 67/78 65/76 67/73
Family history of diabetes (%) 64 65 62 64
Graduated high school (%) 78 78 77 79
Body weight (kg) 65.4  10.4 65.7  11.2 64.9  10.3 65.5  9.8
BMI (kg/m
2) 24.6  3.9 24.7  4.2 24.4  3.8 24.7  3.6
Waist circumference (cm) 87.5  13.2 88.2  13.6 86.7  12.9 87.4  13.1
Systolic blood pressure (mmHg) 131.5  12.3 131.9  11.6 132.0  12.3 130.7  12.3
Diastolic blood pressure (mmHg) 72.4  6.1 72.3  5.8 73.3  6.2 71.5  6.1
Fasting plasma glucose (mg/dl) 92.5  12.8 93.0  11.5 91.7  12.9 92.2  12.4
Plasma glucose at 2 h after oral
glucose load (mg/dl)
168.7  23.2 169.2  22.8 169.3  21.6 168.5  22.4
A1C (%) 5.6  0.3 5.7  0.28 5.6  0.23 5.6  0.27
Serum total cholesterol (mg/dl) 188.7  26.5 189.3  27.1 187.2  25.8 188.6  26.2
Serum LDL cholesterol (mg/dl) 127.7  18.2 128.3  18.7 127.1  17.3 127.3  17.6
Serum triglycerides (mg/dl) 123.6  20.1 124.2  20.3 123.5  21.2 123.4  19.7
Data are means  SD or n (%). There were no signiﬁcant differences in all variables among the groups.
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among the three groups (P  0.01).
The decrease in LDL cholesterol at 6
months was signiﬁcantly greater in the
STH group than in the DES and control
groups. However, at the end of the ﬁrst
year, there was no signiﬁcant difference
betweentheSTHandDESgroups,butthe
values of the two groups were signiﬁ-
cantly lower than that in the control
group (P  0.01).
HDL cholesterol of the control group
decreased signiﬁcantly in comparison
with baseline values (P  0.01), whereas
thatoftheSTHandDESgroupsincreased
signiﬁcantlyoverthe3-yearperiod.There
was no signiﬁcant difference between the
STH and DES groups (supplemental Fig.
3C–F).
Cost beneﬁts
From a health system perspective, the
STH and DES groups cost $1,470 and
$1,090 per patient, respectively, over 3
years. From a societal perspective, the
STH and DES groups cost $21,800 and
$26,350, respectively, for one case of di-
abetes prevented during each trial (15).
CONCLUSIONS— Our results
showed that intervention of a 2-day in-
hospitalprogramwithdiabeteseducation
and support every 3 months for partici-
pants with IGT could prevent or delay
progression to type 2 diabetes. The an-
nual incidence of diabetes in our IGT
population in the control group was
13.2%, which was within the range sug-
gested by epidemiological data (1.5–
15.7%) (6,12,16–22). The data of the
STH group, showing a reduced incidence
of type 2 diabetes (42% reduction in 3
years), was slightly inferior to that in the
DPP (58% in 2.8 years) and the Diabetes
Prevention Study (DPS) (58% in 3.2
years), but was similar to that in the Da
Qing study (31, 42, and 46% in 6 years)
and was superior to that of the Malmo ¨
study (33% in 5 years) (6,12,16,17). Al-
though the exact mechanism(s) of the
outcome noted in our study after a 2-day
in-hospital program is not clear at
present, the reasons that we were able to
achieve these results with such a program
are as follows. Patients with high blood
glucose levels and a diagnosis of IGT dur-
ing a routine medical checkup often do
not have sufﬁcient knowledge about dia-
betes. However, through our 2-day in-
hospital program, the participants had
the opportunity to be instructed on a di-
abetic diet four times, to undergo various
types of guidance classes and education
seminars, and to receive enough informa-
tion about diabetes and the risk of com-
plications to boost motivation. At the ﬁrst
follow-upat3monthsafterthebeginning
of the intervention, most participants’
body weight and laboratory data had im-
proved, and they were praised for achiev-
ingthatgoal,whichmighthavebuilttheir
conﬁdence and increased motivation.
These results suggest that diabetes educa-
tion and support every 3 months are
probably sufﬁcient for maintaining
knowledge and motivation.
We observed a reduced incidence of
diabetes in the STH and DES groups. At
present,weproposeatheoreticalbasisfor
this result. Our study showed that there
were no signiﬁcant differences in the in-
cidence of diabetes after adjustment for
the change in body weight. It indicated
that the weight reduction mostly affected
the incidence of diabetes. But the result
was actually quite close to the criteria of
P  0.05 and indicated that another fac-
tor might also affect it. We found weight
reduction to be 4.3% at 1 year and
2.3%at3yearsintheSTHgroup.How-
ever, our results were lower than those in
theDPP(6.9%at1yearand4.3%at3
years) and DPS (4.7% at 1 year and
3.9% at 2 years) (6,12). The DPP and
DPS were more effective because the in-
terventions were more intense and costly.
On the other hand, our intervention is
more reasonable and has a lesser, but sig-
niﬁcant, effect in reducing diabetes risk.
In addition to the effect of the interven-
tion program, we consider the possibility
that ethnic background also affects the
difference in weight reduction, as sug-
gested by Chen et al. (23).
Several large-scale studies have indi-
cated that lifestyle improvement is effec-
tive in prevention of diabetes, but in most
studies this required intensive supervi-
sion and several staff and was costly
(13,24). As direct and indirect medical
costsinJapanmaybedifferentfromthose
in the U.S. or other countries, because of
how health care is ﬁnanced in general
amongotherissues,thesecannoteasilybe
directly compared. Because our program
ismoresimpliﬁedandrequiresfewerstaff
than conventional studies, we speculate
that the STH intervention may be able to
save both personnel and training costs for
Figure 1—Cumulative incidence of diabetes according to study group. The diagnosis of diabetes
was based on the 2003 criteria of the American Diabetes Association. The incidence of diabetes
differed signiﬁcantly among the three groups (P  0.01 for each comparison). Full line, STH
group; dotted line, DES group; broken line, control group.
Diabetes educational program and diabetes
1952 DIABETES CARE, VOLUME 31, NUMBER 10, OCTOBER 2008one case of diabetes prevented compared
with the DPP lifestyle intervention group
or other conventional studies.
Starting treatment with glucose-
lowering agents before the establishment
of diabetes is another way of reducing
progression to diabetes. However, this is
problematic from the point of view of
health insurance and compliance, which
is often unfavorable when patients who
areasymptomaticforachronicdiseaseare
medicated (25,26). The system for health
insurance may be different in various
countries. For example, in Japan, the use
of medications for IGT is not covered un-
der the government-sponsored health in-
surance system, whereas educational
hospitalization for IGT is. Although we
realize that insurance limitations may ex-
ist in some countries, it would be desir-
ableiftheuseofinsuranceforeducational
hospitalization for IGT was permitted.
The present study had several limita-
tions. The most important of these was
the open-label study design, but we used
the PROBE design, which has great simi-
larity to routine clinical practice. The
sample of participants, from the Joetsu
area of Japan, was geographically, ra-
cially, and ethnically limited. We specu-
lated that the results of self-assessment
about adherence to recommendations
that showed no signiﬁcant differences
among the groups reﬂected the relative
insensitivity of our assessment of diet and
physical activity to measure change or
differences in change between the inter-
vention groups. In addition, the groups
may have differed in various ways that
may have biased the results, e.g., readi-
ness for change, but we did not evaluate
such factors.
In summary, we found in the present
studythatdiabeteseducationandsupport
every 3 months for participants with IGT
could prevent or delay progression to
type 2 diabetes from IGT. Furthermore,
this program was more effective when a
2-day in-hospital program was added,
which might improve the motivation and
will of participants with IGT.
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